Tyrosine-kinase inhibitor

Where the papers sit

16 papers from the last 6 months study tyrosine-kinase inhibitor directly · updated from PubMed 12 Oct 2026

• Precision Cancer Therapy

  Combination and precision strategies are being tested across advanced cancers rather than relying on TKI monotherapy. In hepatocellular carcinoma, camrelizumab, apatinib and radiotherapy, or lenvatinib with ADI-PEG 20, target response and progression-free survival. Stromal remodeling and drug penetration, PIK3CA selection, and HER2 targeting broaden the approach. Hypertension remains a recurring safety issue during VEGF-directed treatment.

  6 papers · 37.5%

• EGFR Resistance in Lung Cancer

  EGFR-mutant lung cancer treatment is moving toward resistance-directed sequencing and mutation-specific inhibitors. Acquired resistance recurs through T790M, C797S, NF-κB/ALDH1A1 signaling and altered sphingolipid metabolism after EGFR-TKIs. Mefatinib and gefitinib are being compared in first-line care, while new compounds target L858R/T790M/C797S disease. Biosensors aim to detect resistance mutations earlier and guide treatment selection.

  5 papers · 31.2%

• Leukemia TKI Outcomes

  Leukemia TKI care is shifting from indefinite treatment toward molecularly guided remission and survivorship management. In chronic myeloid leukemia, treatment-free remission and molecular relapse are defined through comprehensive monitoring, while adherence remains a modifiable determinant of success. Arterial stiffness and other adverse health events highlight cumulative vascular and real-world toxicity. TKI maintenance after brexucabtagene autoleucel extends targeted therapy into Philadelphia chromosome-positive acute lymphoblastic leukemia.

  5 papers · 31.2%